Lead Product(s): Hypoimmunogenic cells
Therapeutic Area: Gene Therapy
Highest Development Status: Undisclosed Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 29, 2020
First research collaboration for immunotolerance UniverCyteTM technology platform, marking launch of new business development and collaboration strategy.